Compare Agilysys Inc (AGYS) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Becton Dickinson and Co — how do they compare? Agilysys Inc trades at $106.39 (market cap $3.00B), while Becton Dickinson and Co trades at $181.02 (market cap $49.41B). The key difference: Becton Dickinson and Co is far larger — about 16.5× Agilysys Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | BDX | |
|---|---|---|
Market Cap | $3.00B | $49.41B |
Sector | Technology | Health |
52-Week High | $141.12 | $185.39 |
52-Week Low | $62.19 | $138.62 |
Enterprise Value | $2.90B | $65.51B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $104.92, down 1.93% on the day, with a bullish technical signal and strong analyst support. Recent Q1 2027 earnings beat expectations, driven by subscription growth and record revenue, prompting raised full-year guidance. The stock shows robust fundamentals with a 63.06% gross margin and 12.99% net income margin, though valuations are elevated with a P/E of 70.01. Institutional sentiment is positive, with all 9 analysts rating it a Buy and a consensus price target of $118.33.
Outlook remains favorable due to earnings momentum and AI-driven hospitality solutions, but risks include high valuation sensitivity and competitive pressures. Upside potential is supported by analyst targets, yet investors should monitor execution on growth forecasts and market volatility.
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
